Trial Profile
The effect of a mineralocorticoid receptor antagonist eplerenone on morning home BP in drug-resistant hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Calcium channel antagonists (Primary) ; Diuretics (Primary) ; Eplerenone (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 22 Jun 2016 New trial record
- 13 Jun 2016 Results published in the Journal of Clinical Hypertension (Greenwich)